The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
ApexOnco Front Page
Recent articles
Parabilis’s zolucatetide bids to be third to a rather small market.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Darovasertib data are promised for the last week of March.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
